

GCCL's Global Projects PORTFOLIO

✓ This infographic is based on the results of clinical trials phases 1 to 3 conducted since GCCL was established in August 2019.

✓ This does not imply that GCCL performed all analyses for these clinical trials or that the analyses were conducted in the countries where the authorization was granted.

> Global Scale Services



Certified by International Accreditation



Global Network



Extensive Experience in Global Projects



Comprehensive Analytical Services

EMA Europe
Regdanvimab Drug approval, etc (Phase 3)
- Approval: 2 cases - NDA: 2 cases

NMPA China
Lurasidone Drug approval, etc (Phase 3)
- NDA: 2 cases

PMDA Japan
Ensitrelvir Fumaric Acid Drug approval, etc (Phase 2/3)
- Approval: 4 cases

Rosdravnadzor Russia
- Approval: 1 case
- NDA: 1 case

NMRA Mongolia

Canada HC

FDA USA
Idursulfase-β orphan drug designation, etc (Phase 1, 3)
- Approval: 3 cases - NDA: 3 cases

MFDS South Korea
Besifovir Drug approval, etc (Phase 3)
- Approval: 12 cases
- Technology Transfer 1 case
- NDA: 3 cases

TITCK Türkiye

Jordan JFDA

Egypt EDA

Saudi Arabia SFDA

India CDSCO
- Approval: 2 cases

Singapore HSA

FDA THAI Thailand

Indonesia BPOM

Philippines PH-FDA

TGA Australia

Ecuador ARCSA

Peru DIGEMID
- Approval: 2 cases

INVIMA Colombia

Bolivia AGEMED

ANVISA Brazil
- Approval: 1 case
- NDA: 1 case


Chile ISP

DINAVISA Paraguay


ANMAT Argentina

> Experience about Approved or Globally Significant Drugs


| By Services



| By Phase



| By Indication



Inquiry

www.gccl.co.kr

+82 31-260-9111

GCCL@gccorp.com

LinkedIn



Blog



Youtube

